• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Exicure, Inc. Announces 1-for-5 Reverse Stock Split

    8/26/24 9:08:00 AM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XCUR alert in real time by email

    Exicure, Inc. (NASDAQ:XCUR, "the Company"))) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the "Reverse Stock Split"). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjusted basis at the open of trading on Wednesday, August 28, 2024 under the new CUSIP number 30205M 309. Exicure's common stock will continue to trade on the NASDAQ Capital Market under the symbol "XCUR". The Reverse Stock Split is an effort to regain compliance with Nasdaq's listing rules.

    The Reverse Stock Split was approved by the Company's stockholders at its Special Meeting of Stockholders held on August 20, 2024, to be effected by the Company's Board of Directors within approved parameters. The Company's Board of Directors approved the Reverse Stock Split at a ratio of 1-for-5 on August 20, 2024.

    As a result of the Reverse Stock Split, each 5 shares of the Company's issued and outstanding common stock will be automatically combined and converted into 1 issued and outstanding share of common stock, resulting in the number of outstanding shares of Exicure's common stock being reduced from approximately 8.65 million to approximately 1.73 million immediately following the effectiveness of the Reverse Stock Split. The Reverse Stock Split will affect all holders of shares of our common stock uniformly and each stockholder will hold the same percentage of our common stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for adjustments that may result from the treatment of fractional shares as described below. The Reverse Stock Split will not affect the number of authorized shares of common stock or the par value of the common stock.

    Stockholders holding their shares in book-entry form will not need to take any action in connection with the Reverse Stock Split. Stockholders will not receive fractional shares of common stock in connection with the Reverse Stock Split. Instead, stockholders who would have been entitled to a fractional share will receive such additional fraction of a share of common stock as is necessary to increase the fractional share to which they were entitled to a full share.

    Additional information on the Reverse Stock Split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission on July 30, 2024, which is available on the SEC's website at www.sec.gov and on the Company's website, www.exicuretx.com.

    About Exicure, Inc.

    Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. There can be no assurance regarding our ability to comply with the Panel's decision and the applicable listing criteria by the deadline or thereafter. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual outcomes to differ materially from the outcomes expressed or implied by this report. Such risks include, among others, the possibility we will not be able to cure existing listing deficiencies, the possibility of additional deficiencies, the risk that the Company may not adequately comply with the terms of the Panel's decision, and the risk that Nasdaq will ultimately delist the Company's common stock. All such factors are difficult to predict and may be beyond the Company's control. The Company undertakes no obligation and does not intend to update or revise any forward-looking statements contained herein, except as required by law or regulation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240826933740/en/

    Get the next $XCUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XCUR

    DatePrice TargetRatingAnalyst
    12/13/2021$2.25 → $0.40Buy → Neutral
    Chardan Capital Markets
    11/23/2021$7.00 → $2.25Buy
    Chardan Capital
    More analyst ratings

    $XCUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exicure downgraded by Chardan Capital Markets with a new price target

    Chardan Capital Markets downgraded Exicure from Buy to Neutral and set a new price target of $0.40 from $2.25 previously

    12/13/21 8:43:28 AM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital reiterated coverage on Exicure with a new price target

    Chardan Capital reiterated coverage of Exicure with a rating of Buy and set a new price target of $2.25 from $7.00 previously

    11/23/21 8:42:55 AM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Exicure with a new price target

    HC Wainwright & Co. reiterated coverage of Exicure with a rating of Buy and set a new price target of $6.00 from $8.00 previously

    5/17/21 7:10:54 AM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XCUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Exicure Hitron Inc. sold $1,162,652 worth of shares (258,367 units at $4.50), decreasing direct ownership by 14% to 1,598,947 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    1/21/26 12:46:19 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Exicure Hitron Inc. sold $3,306,362 worth of Common (734,747 units at $4.50), decreasing direct ownership by 28% to 1,857,314 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    1/20/26 2:09:18 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Exicure Hitron Inc. sold $3,335,724 worth of Common (741,272 units at $4.50), decreasing direct ownership by 22% to 2,592,061 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    1/8/26 8:42:41 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XCUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hitron Systems Inc. bought $8,700,000 worth of shares (2,900,000 units at $3.00), increasing direct ownership by 669% to 3,333,333 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    3/26/25 5:41:19 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Dgp Co., Ltd. bought $711,669 worth of shares (237,223 units at $3.00), increasing direct ownership by 39% to 849,223 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    9/16/24 9:41:12 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XCUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

    REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication of results from a prior Phase 2 clinical study evaluating burixafor (GPC-100/TG-0054), a highly selective CXCR4 inhibitor, in the journal Annals of Hematology. The manuscript, titled "Burixafor, a CXCR4 Inhibitor with a Differentiated Kinetics Profile: Results of a Phase 2 Study for Rapid Cell Mobilization in Multiple Myeloma and Lymphoma Patients Undergoing Transplant," reports results from a 12-participant, multi-center, open-label Phase 2 study (NCT02104427) evaluating burixafor in c

    2/5/26 7:00:00 AM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

    REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it will present a poster at the upcoming 2026 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), taking place February 4-7, 2026, in Salt Lake City, UT. The presentation will serve as an encore of data reported previously, highlighting results from Exicure's open-label, multicenter Phase 2 trial (NCT05561751) evaluating burixafor in patient

    1/21/26 7:00:00 AM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

    REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluating burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPCs) in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT). The data, which showed that approximately 90% of study participants achieved the primary endpoint, were presented today in an oral session at the 67th American Society of Hematology (A

    12/8/25 4:30:00 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XCUR
    SEC Filings

    View All

    Exicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - EXICURE, INC. (0001698530) (Filer)

    1/22/26 4:29:08 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Exicure Inc.

    SCHEDULE 13D/A - EXICURE, INC. (0001698530) (Subject)

    1/20/26 5:48:17 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - EXICURE, INC. (0001698530) (Filer)

    11/17/25 4:52:42 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XCUR
    Leadership Updates

    Live Leadership Updates

    View All

    Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

    Exicure, Inc. (NASDAQ:XCUR, "the Company", "Exicure")), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders on December 17, 2024 (the "Change of Control"), the stockholders of the Company approved a second investment of $8.7 million from HiTron Systems Inc. ("HiTron"), a publicly listed company (KOSPI) in South Korea. This investment is expected to close within a few days depending on regulatory approvals. Also, on December 19, 2024, the Board of Directors (the "Board") of the Company changed the authorized number of directors comprising the Board to nine directors and appointed four new directors

    12/20/24 4:42:00 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

    Exicure, Inc. (NASDAQ:XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of August 21, 2023, Paul Kang, a Class III director, was appointed as Chief Executive Officer of the Company and Jiyoung Hwang, a Class I director, was appointed as Chief Financial Officer of the Company. Mr. Kang and Ms. Hwang succeed Mr. Jung-Sang (Michael) Kim, who stepped down as Chief Executive Officer and Chief Financial Officer last Friday. Additionally, effective as of August 21, 2023, the Board also approved the appointment of Hyuk Joon (Raymond) Ko as a Class III direct

    8/23/23 9:48:00 AM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

    Exicure, Inc. (NASDAQ:XCUR) ("Exicure" or the "Company"), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company's board of directors (the "Board"). The Company today announced that the Board fully supports the strategic vision of Mr. Kim and his ongoing efforts to maximize stockholder v

    5/26/23 4:01:00 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XCUR
    Financials

    Live finance-specific insights

    View All

    Exicure, Inc. Reports Third Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended September 30, 2025. Third Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $4.4 million as of September 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended September 30, 2025, as compared to $0 for the quarter ended September 30, 2024. The increase in R&D expense of $0.9 million for the three months ended September 30, 2025 was due to incurring research and developmen

    11/7/25 4:00:00 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure, Inc. Reports Second Quarter 2025 Financial Results

    Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended June 30, 2025. Second Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $7.9 million as of June 30, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.9 million for the quarter ended June 30, 2025, as compared to $0 for the quarter ended June 30, 2024. The increase in R&D expense of $0.9 million for the three months ended June 30, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. ("GPCR U

    8/8/25 4:01:00 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exicure, Inc. Reports First Quarter 2025 Financial Results

    Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.8 million for the quarter ended March 31, 2025, as compared to $0 for the quarter ended March 31, 2024. The increase in R&D expense of $0.8 million for the three months ended March 31, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. ("G

    6/27/25 4:01:00 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $XCUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Exicure Inc.

    SC 13D/A - EXICURE, INC. (0001698530) (Subject)

    9/16/24 9:38:56 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Exicure Inc.

    SC 13D/A - EXICURE, INC. (0001698530) (Subject)

    8/5/24 6:22:26 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care